A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Part of paid clinical trials in Denver, Colorado.

Sponsor
Eikon Therapeutics
Study ID
NCT06907043
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • EIK1004-001 (IMP1707-001) — DRUG
    PARP1 selective inhibitor

Study Details

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2

Key Dates

Start date
Apr 30, 2025
Status verified
Aug 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
130 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1
    EIK1004 (IMP1707) monotherapy; oral tablet(s) daily (except for the single-dose period). Participants will receive escalating doses of EIK1004 (IMP1707) until progressive disease or discontinuation.

Primary Outcome Measure

Number of Participants who experience a Dose-Limiting Toxicity (DLT) [ Time Frame: (Timeframe: up to 28 days) ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Sarah Cannon Research Institute at HealthOneDenverColorado80218
Shelby Mosier-Murray
[email protected]
720-701-0123
Florida Cancer CenterLake MaryFlorida32746
Alexander Philipovskiy
[email protected]
407-804-6133
Beth Israel Deaconess Medical CenterBostonMassachusetts02215
Gary Barahona
[email protected]
617-975-7474
MD AndersonHoustonTexas77030
Cindy Bang
[email protected]
877-632-6789
NEXT OncologySan AntonioTexas78229
China Whitwer
[email protected]
210-580-9500
NEXT VirginiaFairfaxVirginia22031
Nicole Bryson
[email protected]
703-783-4510

Find similar trials in Denver, CO

By research site
Sarah Cannon Research Institute at HealthOne· Denver, COFlorida Cancer Center· Lake Mary, FLBeth Israel Deaconess Medical Center· Boston, MAMD Anderson· Houston, TXNEXT Oncology· San Antonio, TXNEXT Virginia· Fairfax, VA

Related Studies